Phase 4 N=384 Randomized Treatment

Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles

OHSS (Ovarian Hyperstimulation)

Bottom Line

View on ClinicalTrials.gov: NCT00627406 ↗

Enrolled (actual)

384

Serious AEs

0.0%

Results posted

Nov 2013

Primary outcome: Primary: Frequency of Moderate to Severe OHSS. — 0; 2; 2; 0 participants

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Buserelin and Pregnyl (Drug); Pregnyl (Drug)
Age: Adult · 20+ yrs
Sex: Female
Sponsor: Regionshospitalet Viborg, Skive
Primary completion: Dec 2011

Outcome Measures

Outcome	Result	p-value
PRIMARY Frequency of Moderate to Severe OHSS.	0; 2; 2; 0	—
SECONDARY Pregnancy Rate	17; 15; 37; 36	—

Summary

The purpose of this study is to possibly further improve the clinical outcome and explore the incidence of OHSS in patients, who have final oocyte maturation with GnRHa (Buserelin) in GnRH antagonist IVF/ICSI cycles

Eligibility Criteria

Inclusion Criteria

Patient complying with the conditions for IVF or ICSI treatment
Female age over 20 years and under 40 years
Normal regular cycle and patients with oligomenorrhea
BMI > 18 and 25 follicles on the day of triggering ovulation

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00627406). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.